Masataka Kuwana

List of Publications by Year
in descending order

197	12,473	26630	28297
papers	citations	56 h-index	105 g-index

197	197	197	7904
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Nintedanib for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. New England Journal of Medicine, 2019, 380, 2518-2528.	27.0	1,025
2	Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis and Rheumatism, 2005, 52, 1571-1576.	6.7	627
3	RNA helicase encoded by melanoma differentiationâ€“associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: Association with rapidly progressive interstitial lung disease. Arthritis and Rheumatism, 2009, 60, 2193-2200.	6.7	511
4	Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Respiratory Medicine,the, 2020, 8, 963-974.	10.7	348
5	Standardization of the Modified Rodnan Skin Score for Use in Clinical Trials of Systemic Sclerosis. Journal of Scleroderma and Related Disorders, 2017, 2, 11-18.	1.7	321
6	Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 2013, 8, e60442.	2.5	306
7	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatomyositis. Archives of Dermatology, 2011, 147, 391.	1.4	293
8	Human circulating CD14+ monocytes as a source of progenitors that exhibit mesenchymal cell differentiation. Journal of Leukocyte Biology, 2003, 74, 833-845.	3.3	275
9	Defective vasculogenesis in systemic sclerosis. Lancet, The, 2004, 364, 603-610.	13.7	261
10	Clinical manifestation and prognostic factor in anti-melanoma differentiation-associated gene 5 antibody-associated interstitial lung disease as a complication of dermatomyositis. Rheumatology, 2010, 49, 1713-1719.	1.9	261
11	Anti-MDA5 antibody, ferritin and IL-18 are useful for the evaluation of response to treatment in interstitial lung disease with anti-MDA5 antibody-positive dermatomyositis. Rheumatology, 2012, 51, 1563-1570.	1.9	261
12	Clinical and Prognostic Associations Based on Serum Antinuclear Antibodies in Japanese Patients with Systemic Sclerosis. Arthritis and Rheumatism, 1994, 37, 75-83.	6.7	259
13	The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology, 2012, 51, 1278-1284.	1.9	252
14	Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities. Journal of Scleroderma and Related Disorders, 2017, 2, 137-152.	1.7	243
15	Utility of Antiâ€“Melanoma Differentiationâ€“Associated Gene 5 Antibody Measurement in Identifying Patients With Dermatomyositis and a High Risk for Developing Rapidly Progressive Interstitial Lung Disease: A Review of the Literature and a Metaâ€Analysis. Arthritis Care and Research, 2013, 65, 1316-1324.	3.4	223
16	Anti-NXP2 autoantibodies in adult patients with idiopathic inflammatory myopathies: possible association with malignancy. Annals of the Rheumatic Diseases, 2012, 71, 710-713.	0.9	220
17	Antiâ€“Melanoma Differentiationâ€“Associated Gene 5 Is Associated With Rapidly Progressive Lung Disease and Poor Survival in US Patients With Amyopathic and Myopathic Dermatomyositis. Arthritis Care and Research, 2016, 68, 689-694.	3.4	199
18	Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Modern Rheumatology, 2013, 23, 496-502.	1.8	170

#	Article	IF	Citations
19	Clinical manifestations of dermatomyositis and clinically amyopathic dermatomyositis patients with positive expression of antiâ€“melanoma differentiationâ€“associated gene 5 antibody. Arthritis Care and Research, 2012, 64, 1602-1610.	3.4	156
20	Inflammatory myopathy with anti-signal recognition particle antibodies: case series of 100 patients. Orphanet Journal of Rare Diseases, 2015, 10, 61.	2.7	156
21	Cytokine profiles in polymyositis and dermatomyositis complicated by rapidly progressive or chronic interstitial lung disease. Rheumatology, 2014, 53, 2196-2203.	1.9	153
22	Outcomes of patients with systemic sclerosis treated with rituximab in contemporary practice: a prospective cohort study. Annals of the Rheumatic Diseases, 2019, 78, 979-987.	0.9	142
23	Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial. Annals of the Rheumatic Diseases, 2017, 76, 1219-1227.	0.9	135
24	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). Circulation Journal, 2019, 83, 842-945.	1.6	132
25	Influence of ethnic background on clinical and serologic features in patients with systemic sclerosis and anti-DNA topoisomerase I antibody. Arthritis and Rheumatism, 1999, 42, 465-474.	6.7	127
26	Platelet count response to H. pylori treatment in patients with immune thrombocytopenic purpura with and without H. pylori infection: a systematic review. Haematologica, 2009, 94, 850-856.	3.5	118
27	Sarcoplasmic MxA expression. Neurology, 2017, 88, 493-500.	1.1	118
28	Efficacy and safety of nintedanib in patients with systemic sclerosis-associated interstitial lung disease treated with mycophenolate: a subgroup analysis of the SENSCIS trial. Lancet Respiratory Medicine,the, 2021, 9, 96-106.	10.7	118
29	Endothelial Differentiation Potential of Human Monocyte-Derived Multipotential Cells. Stem Cells, 2006, 24, 2733-2743.	3.2	116
30	Racial differences in the distribution of systemic sclerosisâ€“related serum antinuclear antibodies. Arthritis and Rheumatism, 1994, 37, 902-906.	6.7	115
31	Helicobacter pylori eradication shifts monocyte FcÎ³ receptor balance toward inhibitory FcÎ³RIIB in immune thrombocytopenic purpura patients. Journal of Clinical Investigation, 2008, 118, 2939-49.	8.2	114
32	Clinical and laboratory features of fatal rapidly progressive interstitial lung disease associated with juvenile dermatomyositis. Rheumatology, 2015, 54, 784-791.	1.9	114
33	Antimelanoma Differentiation-associated Gene 5 Antibody: Expanding the Clinical Spectrum in North American Patients with Dermatomyositis. Journal of Rheumatology, 2017, 44, 319-325.	2.0	112
34	Antiâ€“U11/U12 RNP antibodies in systemic sclerosis: A new serologic marker associated with pulmonary fibrosis. Arthritis and Rheumatism, 2009, 61, 958-965.	6.7	105
35	Clinical Utility of an Enzyme-Linked Immunosorbent Assay for Detecting Anti-Melanoma Differentiation-Associated Gene 5 Autoantibodies. PLoS ONE, 2016, 11, e0154285.	2.5	102
36	Initial predictors of poor survival in myositis-associated interstitial lung disease: a multicentre cohort of 497 patients. Rheumatology, 2018, 57, 1212-1221.	1.9	101

#	Article	IF	Citations
37	Performance of Candidate Serum Biomarkers for Systemic Sclerosisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2019, 71, 972-982.	5.6	101
38	Clinically amyopathic dermatomyositis. Current Opinion in Rheumatology, 2010, 22, 639-643.	4.3	90
39	Autoantibodies to RuvBL1 and RuvBL2: A Novel Systemic Sclerosisâ€“Related Antibody Associated With Diffuse Cutaneous and Skeletal Muscle Involvement. Arthritis Care and Research, 2014, 66, 575-584.	3.4	86
40	Anti-CADM-140/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Modern Rheumatology, 2013, 23, 496-502.	1.8	84
41	Myopathy Associated With Antibodies to Signal Recognition Particle. Archives of Neurology, 2012, 69, 728-32.	4.5	82
42	CD4+CD25+Foxp3+ Regulatory T Cells in the Pathophysiology of Immune Thrombocytopenia. Seminars in Hematology, 2013, 50, S43-S49.	3.4	82
43	Anti-Melanoma Differentiation-Associated Gene 5 Antibody is a Diagnostic and Predictive Marker for Interstitial Lung Diseases Associated with Juvenile Dermatomyositis. Journal of Pediatrics, 2011, 158, 675-677.	1.8	79
44	Diagnostic and Prognostic Biomarkers for Chronic Fibrosing Interstitial Lung Diseases With a Progressive Phenotype. Chest, 2020, 158, 646-659.	0.8	79
45	Brief Report: Association of HLAâ€“DRB1*0101/*0405 with susceptibility to antiâ€“melanoma differentiationâ€“associated gene 5 antibodyâ€“positive dermatomyositis in the Japanese population. Arthritis and Rheumatism, 2012, 64, 3736-3740.	6.7	78
46	Transethnic meta-analysis identifies GSDMA and PRDM1 as susceptibility genes to systemic sclerosis. Annals of the Rheumatic Diseases, 2017, 76, 1150-1158.	0.9	77
47	Epidemiology of primary immune thrombocytopenia in children and adults in Japan: a population-based study and literature review. International Journal of Hematology, 2011, 93, 329-335.	1.6	76
48	Elevated Serum Krebs von den Lungen-6 in Early Disease Predicts Subsequent Deterioration of Pulmonary Function in Patients with Systemic Sclerosis and Interstitial Lung Disease. Journal of Rheumatology, 2016, 43, 1825-1831.	2.0	74
49	Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): randomised, double-blind, placebo-controlled multicentre trial. Annals of the Rheumatic Diseases, 2020, 79, 618-625.	0.9	71
50	T cells that are autoreactive to Î²2-glycoprotein I in patients with antiphospholipid syndrome and healthy individuals. Arthritis and Rheumatism, 2000, 43, 65-75.	6.7	70
51	Enzyme-linked immunosorbent assays for detection of anti-transcriptional intermediary factor-1 gamma and anti-Mi-2 autoantibodies in dermatomyositis. Journal of Dermatological Science, 2016, 84, 272-281.	1.9	69
52	Sensitivity and specificity of 2010 rheumatoid arthritis classification criteria. Rheumatology, 2011, 50, 1268-1274.	1.9	68
53	Serum interferon-Î± is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Modern Rheumatology, 2015, 25, 85-89.	1.8	66
54	PLD4 as a novel susceptibility gene for systemic sclerosis in a Japanese population. Arthritis and Rheumatism, 2013, 65, 472-480.	6.7	62

#	Article	IF	Citations
55	Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Journal of Rheumatology, 2007, 34, 1012-8.	2.0	62
56	The Role of Autoreactive T-Cells in the Pathogenesis of Idiopathic Thrombocytopenic Purpura. International Journal of Hematology, 2005, 81, 106-112.	1.6	60
57	Risk Prediction Modeling Based on a Combination of Initial Serum Biomarker Levels in Polymyositis/Dermatomyositisâ€“Associated Interstitial Lung Disease. Arthritis and Rheumatology, 2021, 73, 677-686.	5.6	60
58	KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease. Journal of Rheumatology, 2018, 45, 1153-1158.	2.0	56
59	Analysis of dermatomyositisâ€specific autoantibodies and clinical characteristics in Japanese patients. Journal of Dermatology, 2011, 38, 973-979.	1.2	55
60	Distinct profiles of myositis-specific autoantibodies in Chinese and Japanese patients with polymyositis/dermatomyositis. Clinical Rheumatology, 2015, 34, 1627-1631.	2.2	55
61	Progression of Interstitial Lung Disease in Systemic Sclerosis: The Importance of Pneumoproteins Krebs von den Lungen 6 and CCL18. Arthritis and Rheumatology, 2019, 71, 2059-2067.	5.6	55
62	Elevated Levels of Pentraxin 3 in Systemic Sclerosis: Associations With Vascular Manifestations and Defective Vasculogenesis. Arthritis and Rheumatology, 2015, 67, 498-507.	5.6	54
63	Association of Human Leukocyte Antigen Class II Genes with Autoantibody Profiles, but not with Disease Susceptibility in Japanese Patients with Systemic Sclerosis.. Internal Medicine, 1999, 38, 336-344.	0.7	53
64	Clinical and histological findings associated with autoantibodies detected by RNA immunoprecipitation in inflammatory myopathies. Journal of Neuroimmunology, 2014, 274, 202-208.	2.3	53
65	The role of chest CT in deciphering interstitial lung involvement: systemic sclerosis versus COVID-19. Rheumatology, 2022, 61, 1600-1609.	1.9	53
66	Serum ferritin correlates with activity of anti-MDA5 antibody-associated acute interstitial lung disease as a complication of dermatomyositis. Modern Rheumatology, 2011, 21, 223-227.	1.8	51
67	Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management. Annals of the Rheumatic Diseases, 2020, 79, 724-726.	0.9	51
68	Immune Checkpoint Inhibitor-Induced Myositis: a Case Report and Literature Review. Current Rheumatology Reports, 2019, 21, 10.	4.7	49
69	2019 Diagnostic criteria for mixed connective tissue disease (MCTD): From the Japan research committee of the ministry of health, labor, and welfare for systemic autoimmune diseases. Modern Rheumatology, 2021, 31, 29-33.	1.8	49
70	Initial laboratory findings useful for predicting the diagnosis of idiopathic thrombocytopenic purpura. American Journal of Medicine, 2005, 118, 1026-1033.	1.5	48
71	Critical role of CD4+CD25+ regulatory T cells in preventing murine autoantibody-mediated thrombocytopenia. Experimental Hematology, 2012, 40, 279-289.	0.4	47
72	Clinical and serological features of patients with dermatomyositis complicated by spontaneous pneumomediastinum. Clinical Rheumatology, 2016, 35, 489-493.	2.2	46

#	Article	IF	Citations
73	Circulating Anti-Nuclear Antibodies in Systemic Sclerosis: Utility in Diagnosis and Disease Subsetting. Journal of Nippon Medical School, 2017, 84, 56-63.	0.9	46
74	2020 guide for the diagnosis and treatment of interstitial lung disease associated with connective tissue disease. Respiratory Investigation, 2021, 59, 709-740.	1.8	45
75	Identification of an immunodominant epitope on RNA polymerase III recognized by systemic sclerosis sera: Application to enzyme-linked immunosorbent assay. Arthritis and Rheumatism, 2002, 46, 2742-2747.	6.7	44
76	Autoreactive T cells to topoisomerase I in monozygotic twins discordant for systemic sclerosis. Arthritis and Rheumatism, 2001, 44, 1654-1659.	6.7	43
77	Effects of a Helicobacter pylori eradication regimen on anti-platelet autoantibody response in infected and uninfected patients with idiopathic thrombocytopenic purpura. Haematologica, 2006, 91, 1436-7.	3.5	43
78	Human Pentraxin 3 (PTX3) as a Novel Biomarker for the Diagnosis of Pulmonary Arterial Hypertension. PLoS ONE, 2012, 7, e45834.	2.5	42
79	Brief Report: Impaired In Vivo Neovascularization Capacity of Endothelial Progenitor Cells in Patients With Systemic Sclerosis. Arthritis and Rheumatology, 2014, 66, 1300-1305.	5.6	40
80	Gottron Papules and Gottron Sign with Ulceration: A Distinctive Cutaneous Feature in a Subset of Patients with Classic Dermatomyositis and Clinically Amyopathic Dermatomyositis. Journal of Rheumatology, 2016, 43, 1735-1742.	2.0	39
81	Versican is upregulated in circulating monocytes in patients with systemic sclerosis and amplifies a CCL2-mediated pathogenic loop. Arthritis Research and Therapy, 2013, 15, R74.	3.5	38
82	Reference guide for management of adult immune thrombocytopenia in Japan: 2019 Revision. International Journal of Hematology, 2020, 111, 329-351.	1.6	38
83	HLA-DRB1 Alleles as Genetic Risk Factors for the Development of Anti-MDA5 Antibodies in Patients with Dermatomyositis. Journal of Rheumatology, 2017, 44, 1389-1393.	2.0	37
84	Seasonal and residential clustering at disease onset of anti-MDA5-associated interstitial lung disease. RMD Open, 2020, 6, e001202.	3.8	37
85	COVID-19 vaccination in autoimmune disease (COVAD) survey protocol. Rheumatology International, 2022, 42, 23-29.	3.0	37
86	Discordance in Global Assessments Between Patient and Estimator in Patients with Newly Diagnosed Rheumatoid Arthritis: Associations with Progressive Joint Destruction and Functional Impairment. Journal of Rheumatology, 2014, 41, 1061-1066.	2.0	34
87	Initial combination therapy of ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH) in the modified intention-to-treat population of the AMBITION study: post hoc analysis. Annals of the Rheumatic Diseases, 2020, 79, 626-634.	0.9	34
88	Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Research and Therapy, 2010, 12, R205.	3.5	33
89	Quantification of circulating endothelial progenitor cells in systemic sclerosis: a direct comparison of protocols. Annals of the Rheumatic Diseases, 2012, 71, 617-620.	0.9	33
90	An immunodominant epitope on DNA topoisomerase I is conformational in nature: Heterogeneity in its recognition by systemic sclerosis sera. Arthritis and Rheumatism, 1999, 42, 1179-1188.	6.7	32

#	Article	IF	Citations
91	Autoantibodies to RNA polymerases recognize multiple subunits and demonstrate cross-reactivity with RNA polymerase complexes. Arthritis and Rheumatism, 1999, 42, 275-284.	6.7	32
92	Amyopathic dermatomyositis developing rapidly progressive interstitial lung disease with elevation of anti-CADM-140/MDA5 autoantibodies. Modern Rheumatology, 2012, 22, 625-629.	1.8	32
93	Comparison of radioimmunoprecipitation versus antigen-specific assays for identification of myositis-specific autoantibodies in dermatomyositis patients. Modern Rheumatology, 2014, 24, 945-948.	1.8	32
94	Choosing the right biomarkers to predict ILD in myositis. Nature Reviews Rheumatology, 2016, 12, 504-506.	8.0	31
95	Induction of immune tolerance to platelet antigen by short-term thrombopoietin treatment in a mouse model of immune thrombocytopenia. International Journal of Hematology, 2014, 100, 341-344.	1.6	30
96	Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Therapeutic Advances in Musculoskeletal Disease, 2021, 13, 1759720X2110324.	2.7	30
97	Nintedanib: New indication for systemic sclerosis-associated interstitial lung disease. Modern Rheumatology, 2020, 30, 225-231.	1.8	29
98	Serum chemokine levels as prognostic markers in patients with early systemic sclerosis: a multicenter, prospective, observational study. Modern Rheumatology, 2013, 23, 1076-1084.	1.8	28
99	Myositis-specific autoantibodies in Japanese patients with juvenile idiopathic inflammatory myopathies. Modern Rheumatology, 2019, 29, 351-356.	1.8	27
100	The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis. Arthritis Research and Therapy, 2020, 22, 117.	3.5	27
101	Current and Future Outlook on Disease Modification and Defining Low Disease Activity in Systemic Sclerosis. Arthritis and Rheumatology, 2020, 72, 1049-1058.	5.6	27
102	Association of Functional Microsatellites in the Human Type I Collagen Î±2 Chain (COL1A2) Gene with Systemic Sclerosis. Biochemical and Biophysical Research Communications, 2000, 272, 36-40.	2.1	26
103	Efficacy and safety of TNF-Î± antagonists and tocilizumab in Takayasu arteritis: multicentre retrospective study of 209 patients. Rheumatology, 2022, 61, 1376-1384.	1.9	26
104	Low positive titer of anti-melanoma differentiation-associated gene 5 antibody is not associated with a poor long-term outcome of interstitial lung disease in patients with dermatomyositis. Respiratory Investigation, 2018, 56, 464-472.	1.8	25
105	Primary systemic sclerosis heart involvement: A systematic literature review and preliminary data-driven, consensus-based WSF/HFA definition. Journal of Scleroderma and Related Disorders, 2022, 7, 24-32.	1.7	25
106	Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease. Respiratory Investigation, 2017, 55, 24-32.	1.8	24
107	Î²2-Glycoprotein I-Reactive T Cells in Autoimmune Disease. Frontiers in Immunology, 2018, 9, 2836.	4.8	24
108	Antiviral proinflammatory phenotype of monocytes in anti-MDA5 antibody-associated interstitial lung disease. Rheumatology, 2022, 61, 806-814.	1.9	23

#	Article	IF	Citations
109	High-dose intravenous immunoglobulin therapy for rapidly progressive interstitial pneumonitis accompanied by anti-melanoma differentiation-associated gene 5 antibody-positive amyopathic dermatomyositis. European Journal of Rheumatology, 2015, 2, 83-85.	0.6	23
110	HLA loci predisposing to immune TTP in Japanese: potential role of the shared ADAMTS13 peptide bound to different HLA-DR. Blood, 2020, 135, 2413-2419.	1.4	22
111	Early diagnosis and treatment for remission of clinically amyopathic dermatomyositis complicated by rapid progress interstitial lung disease: a report of two cases. Modern Rheumatology, 2013, 23, 190-194.	1.8	21
112	Tocilizumab is effective against polymyalgia rheumatica: experience in 13 intractable cases. RMD Open, 2015, 1, e000162.	3.8	21
113	Performance evaluation of a commercial line blot assay system for detection of myositis- and systemic sclerosis-related autoantibodies. Clinical Rheumatology, 2020, 39, 3489-3497.	2.2	21
114	Nintedanib in Patients With Systemic Sclerosisâ€“Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score. Arthritis and Rheumatology, 2022, 74, 518-526.	5.6	21
115	Therapeutic Approaches to Systemic Sclerosis: Recent Approvals and Future Candidate Therapies. Clinical Reviews in Allergy and Immunology, 2023, 64, 239-261.	6.5	20
116	COVID-19 vaccination-related adverse events among autoimmune disease patients: results from the COVAD study. Rheumatology, 2022, 62, 65-76.	1.9	19
117	Risk factors for skin, mucosal, and organ bleeding in adults with primary ITP: a nationwide study in Japan. Blood Advances, 2020, 4, 1648-1655.	5.2	17
118	Endothelial cells and endothelial progenitor cells in the pathogenesis of systemic sclerosis. European Journal of Rheumatology, 2020, 7, 139-146.	0.6	17
119	FcÎ³ receptor IIB gene polymorphism in adult Japanese patients with primary immune thrombocytopenia. Blood, 2013, 122, 1991-1992.	1.4	16
120	Comparison of anti-OJ antibody detection assays between an immunoprecipitation assay and line blot assay. Modern Rheumatology, 2017, 27, 551-552.	1.8	16
121	Evaluation of the alternative classification criteria of systemic lupus erythematosus established by Systemic Lupus International Collaborating Clinics (SLICC). Modern Rheumatology, 2018, 28, 642-648.	1.8	16
122	Efficacy and safety of nintedanib in Asian patients with systemic sclerosis-associated interstitial lung disease: Subgroup analysis of the SENSCIS trial. Respiratory Investigation, 2021, 59, 252-259.	1.8	15
123	Updates on genetics in systemic sclerosis. Inflammation and Regeneration, 2021, 41, 17.	3.7	15
124	Association of psoriasis with Hashimoto's thyroiditis, SjÃ¶gren's syndrome and dermatomyositis. Journal of Dermatology, 2016, 43, 711-712.	1.2	14
125	Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Review of Clinical Immunology, 2020, 16, 79-89.	3.0	14
126	A unique thymus-derived regulatory T cell subset associated with systemic lupus erythematosus. Arthritis Research and Therapy, 2020, 22, 88.	3.5	14

#	Article	IF	Citations
127	Nintedanib in patients with systemic sclerosis-associated interstitial lung disease: A Japanese population analysis of the SENSCIS trial. Modern Rheumatology, 2021, 31, 141-150.	1.8	14
128	HLA class II alleles in systemic sclerosis patients with anti-RNA polymerase I/III antibody: associations with subunit reactivities. Journal of Rheumatology, 2003, 30, 2392-7.	2.0	14
129	Vaccine hesitancy in patients with autoimmune diseases: Data from the coronavirus disease-2019 vaccination in autoimmune diseases study. Indian Journal of Rheumatology, 2022, 17, 188.	0.4	14
130	Add-on tocilizumab versus conventional treatment for systemic sclerosis, and cytokine analysis to identify an endotype to tocilizumab therapy. Modern Rheumatology, 2019, 29, 134-139.	1.8	12
131	T cells from induced and spontaneous models of SLE recognize a common T cell epitope on Î²2-glycoprotein I. Cellular and Molecular Immunology, 2019, 16, 685-693.	10.5	12
132	Chest wall muscle atrophy as a contributory factor for forced vital capacity decline in systemic sclerosis-associated interstitial lung disease. Rheumatology, 2021, 60, 250-255.	1.9	12
133	Clinical impact of myositis-specific autoantibodies on long-term prognosis of juvenile idiopathic inflammatory myopathies: multicentre study. Rheumatology, 2021, 60, 4821-4831.	1.9	12
134	Coexistence of anti-melanoma differentiation-associated gene 5 and anti-aminoacyl-transfer RNA synthetase antibodies in a patient with dermatomyositis and rapidly progressive and relapsing interstitial lung disease. Modern Rheumatology Case Reports, 2017, 1, 3-8.	0.7	11
135	Two cases with autoantibodies to small ubiquitinâ€like modifier activating enzyme: A potential unique subset of dermatomyositisâ€associated interstitial lung disease. International Journal of Rheumatic Diseases, 2019, 22, 1582-1586.	1.9	11
136	Recent progress and missing gaps to achieve goal in the care of systemic sclerosisâ€“associated interstitial lung disease. Journal of Scleroderma and Related Disorders, 2020, 5, 3-5.	1.7	9
137	Clinical worsening following discontinuation of tocilizumab in diffuse cutaneous systemic sclerosis: a single-centre experience in Japan. Rheumatology, 2022, 61, 4491-4496.	1.9	9
138	Incidence Rate and Prevalence of Systemic Sclerosis and Systemic Sclerosis-Associated Interstitial Lung Disease in Japan: Analysis Using Japanese Claims Databases. Advances in Therapy, 2022, 39, 2222-2235.	2.9	9
139	Distinct arthropathies of the hands in patients with anti-aminoacyl tRNA synthetase antibodies: usefulness of autoantibody profiles in classifying patients. Rheumatology, 2014, 53, 1120-1124.	1.9	8
140	Oral vasopressin receptor antagonist tolvaptan in right heart failure due to pulmonary hypertension. European Respiratory Journal, 2015, 46, 283-286.	6.7	8
141	A To-Do List at Diagnosis of Systemic Sclerosis with Positive Anti-RNA Polymerase III Antibodies. Journal of Rheumatology, 2017, 44, 550-552.	2.0	8
142	Anti-MDA5 antibody-positive rapidly progressive interstitial pneumonia without cutaneous manifestations. Respiratory Medicine Case Reports, 2019, 26, 193-196.	0.4	8
143	Improved quantification of a commercial enzyme-linked immunosorbent assay kit for measuring anti-MDA5 antibody. Modern Rheumatology, 2019, 29, 140-145.	1.8	8
144	Complex Pathophysiology of Pulmonary Hypertension Associated with Systemic Sclerosis: Potential Unfavorable Effects of Vasodilators. Journal of Scleroderma and Related Disorders, 2017, 2, 92-99.	1.7	7

#	Article	IF	Citations
145	Performance evaluation of a line blot assay system for detection of antiâ€PMâ€Scl antibody in Japanese patients with systemic sclerosis. International Journal of Rheumatic Diseases, 2019, 22, 1746-1751.	1.9	7
146	Use of vonoprazan, a novel potassium-competitive acid blocker, for the treatment of proton pump inhibitor-refractory reflux esophagitis in patients with systemic sclerosis. Journal of Scleroderma and Related Disorders, 2022, 7, 57-61.	1.7	7
147	The development of quality indicators for systemic lupus erythematosus using electronic health data: A modified RAND appropriateness method. Modern Rheumatology, 2020, 30, 525-531.	1.8	6
148	Initial predictors of skin thickness progression in patients with diffuse cutaneous systemic sclerosis: Results from a multicentre prospective cohort in Japan. Modern Rheumatology, 2021, 31, 386-393.	1.8	6
149	Efficacy and safety of nintedanib in Japanese patients with progressive fibrosing interstitial lung diseases: Subgroup analysis of the randomised, double-blind, placebo-controlled, phase 3 INBUILD trial. Respiratory Medicine, 2021, 187, 106574.	2.9	6
150	Clinical Relevance of the Serial Measurement of Krebs von den Lungen-6 Levels in Patients with Systemic Sclerosis-Associated Interstitial Lung Disease. Diagnostics, 2021, 11, 2007.	2.6	6
151	Should we reconsider the definition of elderly-onset rheumatoid arthritis in an ageing society?. Modern Rheumatology, 2022, 32, 323-329.	1.8	6
152	Three cases of interstitial pneumonia with anti-signal recognition particle antibody. Allergology International, 2017, 66, 485-487.	3.3	5
153	Cluster of differentiation 30 expression in lacrimal gland and conjunctival tissues in patients with SjÃ¶gren's syndrome. Medicine (United States), 2019, 98, e16390.	1.0	5
154	Nintedanib for the treatment of systemic sclerosis-associated interstitial lung disease. Expert Review of Clinical Immunology, 2020, 16, 547-560.	3.0	5
155	Current monitoring and treatment of progressive fibrosing interstitial lung disease: a survey of physicians in Japan, the United States, and the European Union. Current Medical Research and Opinion, 2021, 37, 327-339.	1.9	5
156	Rapid Initiation of Intravenous Epoprostenol Infusion Is the Favored Option in Patients with Advanced Pulmonary Arterial Hypertension. PLoS ONE, 2015, 10, e0121894.	2.5	5
157	Outcomes in patients with systemic sclerosis undergoing early vs delayed intervention with potential disease-modifying therapies. Rheumatology, 2022, 61, 3677-3685.	1.9	5
158	Mortality Risk Stratification Using Cluster Analysis in Patients With Myositis-Associated Interstitial Lung Disease Receiving Initial Triple-Combination Therapy. Frontiers in Medicine, 2022, 9, .	2.6	5
159	A multianalyte assay for the detection of dermatomyositis-related autoantibodies based on immunoprecipitation combined with immunoblotting. Modern Rheumatology, 2023, 33, 543-548.	1.8	5
160	Dual phosphodiesterase type 5 inhibitor therapy for refractory pulmonary arterial hypertension: a pilot study. BMC Pulmonary Medicine, 2015, 15, 62.	2.0	4
161	Utility of dermatomyositis-specific autoantibodies for diagnosis and clinical subsetting. International Journal of Clinical Rheumatology, 2015, 10, 257-271.	0.3	4
162	Presence and Implications of <scp>Antiâ€Angiotensin Converting Enzymeâ€2</scp> Immunoglobulin M Antibodies in <scp>Antiâ€Melanomaâ€Differentiationâ€Associated</scp> 5 Dermatomyositis. ACR Open Rheumatology, 2022, 4, 457-463.	2.1	4

#	Article	IF	Citations
163	Cost-effectiveness analyses of biologic and targeted synthetic disease-modifying anti-rheumatic diseases in patients with rheumatoid arthritis: Three approaches with a cohort simulation and real-world data. Modern Rheumatology, 2023, 33, 302-311.	1.8	4
164	RXRB Is an MHC-Encoded Susceptibility Gene Associated with Anti-Topoisomerase IÂAntibody-Positive Systemic Sclerosis. Journal of Investigative Dermatology, 2017, 137, 1878-1886.	0.7	3
165	Predictive factors for sustained remission with stratification by myositis-specific autoantibodies in adult polymyositis/dermatomyositis. Rheumatology, 2019, 59, 586-593.	1.9	3
166	A case of cancerâ€associated myositis with antiâ€Miâ€2 antibody: Falseâ€positive antiâ€transcriptional intermediary factor 1â€Î³ antibody by commercial enzymeâ€linked immunosorbent assay. International Journal of Rheumatic Diseases, 2019, 22, 1335-1339.	1.9	3
167	Infratentorial onset of progressive multifocal leukoencephalopathy in a patient with systematic lupus erythematosus complicated with lymphoma: a case report. Modern Rheumatology Case Reports, 2021, 5, 272-277.	0.7	3
168	Identification of Molecular Factors Required for Transdifferentiation of Human Circulating Monocytes into Multipotential Cells.. Blood, 2007, 110, 2408-2408.	1.4	3
169	What do we learn from immunomodulation in patients with immune thrombocytopenia?. Seminars in Hematology, 2016, 53, S27-S30.	3.4	2
170	Mouse immune thrombocytopenia is associated with Th1 bias and expression of activating FcÎ³ receptors. International Journal of Hematology, 2017, 105, 598-605.	1.6	2
171	OP0183â€…EFFICACY AND SAFETY OF RIOCIGUAT IN PATIENTS WITH EARLY DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS AND INTERSTITIAL LUNG DISEASE (SSC-ILD): RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		2
172	Infection or Autoimmunity? The Clinical Challenge of Interstitial Lung Disease in Systemic Sclerosis During the COVID-19 Pandemic. Journal of Rheumatology, 2021, 48, 790-792.	2.0	2
173	Splenic Macrophages Maintain the Anti-Platelet Autoimmune Response Via Uptake of Opsonized Platelets in Patients with Chronic ITP.. Blood, 2005, 106, 221-221.	1.4	2
174	Dermatomyositis-Associated Autoantibodies: TIF1-Î³, NXP2, and MDA5. , 2020, , 193-198.		2
175	Development of an Automated Chemiluminescent Enzyme Immunoassay for Measuring Thrombopoietin in Human Plasma. Diagnostics, 2022, 12, 313.	2.6	2
176	Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patientsâ€™ cohort. Journal of Dermatological Science, 2021, 103, 53-56.	1.9	1
177	Inflammation and pathogenic fibrosis in human ocular chronic graft versus host disease. Inflammation and Regeneration, 2008, 28, 529-536.	3.7	1
178	Role of Myositis Autoantibodies in Management and Prognosis. , 2020, , 175-180.		1
179	Personalized medicine for connective tissue disease: Historical and future perspectives. Personalized Medicine Universe, 2018, 7, 1-6.	0.3	0
180	Fos-related antigen-1 transgenic mouse as a model for systemic sclerosis: A potential role of M2 polarization. Journal of Scleroderma and Related Disorders, 2019, 4, 137-148.	1.7	0

#	Article	IF	Citations
181	FRI0303â€…THE EFFECTS OF RIOCIGUAT ON RAYNAUDâ€™S PHENOMENON AND DIGITAL ULCERS IN PATIENTS WITH DIFFUSE SYSTEMIC SCLEROSIS: RESULTS FROM THE PHASE IIB RISE-SSC STUDY. , 2019, , .		0
182	OP0067â€…UTILITY OF RISK STRATIFICATION IN PREDICTING OUTCOMES OF INITIAL MONOTHERAPY VERSUS COMBINATION THERAPY IN PULMONARY ARTERIAL HYPERTENSION ASSOCIATED WITH CONNECTIVE TISSUE DISEASE: A POST-HOC ANALYSIS OF THE AMBITION STUDY. , 2019, , .		0
183	Joint contractures responsive to immunosuppressive therapy in a girl with childhoodâ€onset systemic sclerosis doubleâ€seropositive for rare antiâ€nucleolar autoantibodies: a case report. Pediatric Rheumatology, 2021, 19, 37.	2.1	0
184	Clinical Features and Effects of Eradication on Helicobacter Pylori Positive 207 ITP Cases in Japan.. Blood, 2004, 104, 2071-2071.	1.4	0
185	Therapeutic Action of Helicobacter pylori (H. pylori) Eradication in Patients with Chronic ITP - Lessons from Eradication Therapy on H. pylori-Negative Patients.. Blood, 2004, 104, 2070-2070.	1.4	0
186	Impaired Platelet Production and Autoantibody-Mediated Platelet Destruction Are Two Major Causes for Prolonged Thrombocytopenia after Allogeneic HSCT.. Blood, 2004, 104, 2256-2256.	1.4	0
187	Multi-Lineage Potential of Human Monocyte-Derived Mesenchymal Progenitors (MOMPs).. Blood, 2004, 104, 3595-3595.	1.4	0
188	Initial Laboratory Findings Useful for Predicting the Diagnosis of Chronic ITP: Results of a Multicenter Prospective Study.. Blood, 2004, 104, 2061-2061.	1.4	0
189	A regulatory T cell-deficient mouse model as a useful tool for evaluating the pathophysiology of human immune thrombocytopenia. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 605-610.	0.1	0
190	17. Importance of Early Diagnosis and Treatment in Patients with Systemic Sclerosis. The Journal of the Japanese Society of Internal Medicine, 2016, 105, 1864-1869.	0.0	0
191	Endothelial Progenitor Cells. , 2016, , 39-56.		0
192	T-Cell Abnormalities. , 2017, , 63-72.		0
193	Current understanding of the mechanisms for autoantibody production. Japanese Journal of Thrombosis and Hemostasis, 2018, 29, 243-250.	0.1	0
194	Next-Generation Sequencing of HLA Loci Identifies Predisposing and Protective Factors for Immune-Mediated Thrombotic Thrombocytopenic Purpura in a Japanese Population. Blood, 2019, 134, 1085-1085.	1.4	0
195	Branched chain amino acids in the treatment of polymyositis and dermatomyositis: a phase II/III, multi-centre, randomized controlled trial. Rheumatology, 2022, , .	1.9	0
196	Immune-mediated thrombotic thrombocytopenic purpura and HLA. Major Histocompatibility Complex, 2022, 29, 42-51.	0.1	0
197	Severe digital ischemia as an unrecognized manifestation in patients with antisynthetase autoantibodies: Case series and systematic literature review. Journal of Scleroderma and Related Disorders, 0, , 239719832210908.	1.7	0